Author: Claire Hornung

Fibroblasts and Tissue Destruction in Arthritic Diseases

Posted on by Claire Hornung

This webinar focuses on the intricate interplay between fibroblasts and arthritic diseases. Our panel of experts will unravel mechanisms behind tissue damage and repair, discussing fibroblast activation, collagen overproduction, and scar tissue formation.

Discover how blood-based biomarkers of extracellular matrix destruction offer insights into treatment effectiveness and patient well-being. Our speakers will also give insights into PRIME cells’ role in heralding rheumatoid arthritis flare-ups and delve into the molecular underpinnings of symptoms like pain and morning stiffness.

Agenda

  • Fibroblast Activation in Arthritis – Dr. Adam Croft
  • PRIME cells in Rheumatoid Arthritis Flares – Dr. Dana Orange
  • Identification of Fibrotic and Fibrolytic Endotypes in Rheumatic Disease Cohorts – Dr. Anne Bay-Jensen
  • General discussion and questions
Watch the replay

We will explore how measuring tissue damage through blood markers can offer insights into treatment effectiveness and patient experiences. A segment is dedicated to PRIME cells, fibroblast-like entities in blood that signal rheumatoid arthritis flares. We will also delve into the molecular basis of symptoms like pain, morning stiffness, and flares in rheumatoid arthritis.

This webinar spotlights the buzz around developing fresh therapies targeting fibroblasts and fibrosis in arthritic diseases. By sharing the latest research, we aim to shed light on the specific roles and types of fibroblasts driving disease progression and outcomes.

Scientific topics and speakers

In this edition of the ECM Pharmacology Symposium Series, we’re diving into the realm of fibroblasts and their relevance in arthritic diseases. These cells are key players in disease progression, responsible for crafting collagen and extracellular matrix proteins that build the foundation of tissues. In arthritic conditions, activated fibroblasts kick into overdrive, generating excess matrix components, leading to the formation of scar tissue, or fibrosis, with potential impact on joints and tissues.

We will explore how measuring tissue damage through blood markers can offer insights into treatment effectiveness and patient experiences. A segment is dedicated to PRIME cells, fibroblast-like entities in blood that signal rheumatoid arthritis flares. We will also delve into the molecular basis of symptoms like pain, morning stiffness, and flares in rheumatoid arthritis.

This webinar spotlights the buzz around developing fresh therapies targeting fibroblasts and fibrosis in arthritic diseases. By sharing the latest research, we aim to shed light on the specific roles and types of fibroblasts driving disease progression and outcomes.

Dr. Adam Croft

  • Dr. Adam Croft is a Professor of Translational Rheumatology at the University of Birmingham and also serves as a Consultant Rheumatologist at University Hospitals Birmingham.
  • He holds a senior research fellowship from the Kennedy Trust for Rheumatology Research.
  • Dr. Croft’s research program encompasses the entire spectrum of inflammatory arthritis, spanning from children to adults.
  • His goal is to establish connections between synovial tissue pathology and specific disease outcomes and treatment responses.
  • He places a strong emphasis on the discovery of novel and actionable therapeutic targets, leveraging cutting-edge single-cell profiling technologies.
  • Dr. Croft’s research is particularly focused on understanding the role of tissue resident fibroblasts in perpetuating inflammation in immune-mediated inflammatory diseases and finding therapeutic strategies to target these cells effectively.

Dr. Dana Orange

  • Dr. Dana Orange, MD, MSc, holds the position of Associate Professor of Clinical Investigation at Rockefeller University and serves as an Assistant Attending of Rheumatology at the Hospital for Special Surgery.
  • She earned her medical degree from Weill Cornell Medical College, Cornell University, and obtained her MSc from Rockefeller University.
  • Dr. Orange completed her Internal Medicine Residency at New York Presbyterian Hospital and her Rheumatology Fellowship at the Hospital for Special Surgery.
  • Her research is dedicated to unraveling the molecular mechanisms behind symptoms associated with rheumatoid arthritis, including pain, morning stiffness, and flares.

Dr. Anne Bay-Jensen

  • Dr. Anna Bay-Jensen serves as the Chief Technology Officer (CTO) and Director of ImmunoScience at Nordic Bioscience, where she has been part of the team since 2008, starting as a post-doc and advancing to leadership roles.
  • She is recognized for her hard work, innovative thinking, and leadership in the development of novel biomarkers that support precision medicine, an ongoing journey.
  • Dr. Bay-Jensen’s research primarily focuses on biomarkers related to rheumatic diseases, with a particular emphasis on joints and rheumatoid arthritis, a field she has dedicated two decades to.
  • She has an impressive academic record with 10,459 citations, an h-index of 60, and an i10-index of 191, reflecting her significant contributions to the field.
  • Her research has highlighted the importance of extracellular matrix remodeling as a common denominator in connective tissue diseases and the development of novel combinations of post-translational modification (PTM) neo-epitopes as tissue-specific biochemical markers.

 

Watch the replay

Get in touch

Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
+45 4452 5252 Contact us via email!

    Q2 2023 Publication Digest

    Posted on by Claire Hornung

    We have collected some of our best publications that we and our collaborators worked on in the second quarter of 2023—in no particular order. We invite you to browse and read according to your interests!

    Hepatology

    Alcohol-related liver disease (ArLD) leads to progressive liver-related outcomes and death, necessitating vigilant monitoring. Examining patients with ArLD over an average of 5.2 years, the PRO-C3-based score known as ALPACA (PRO-C3/AST/ALT, Platelets) demonstrated remarkable prognostic capability for liver-related events.

    Comparatively, FIB-4, single markers like PRO-C3, ADAPT, ELF, and liver stiffness measures were all surpassed by the predictive efficacy of the ALPACA score in assessing outcomes for ArLD patients.

    Read article

    Respiratory

    Fibronectin is a key protein for matrix organization and has been described as the glue of the extracellular matrix. The novel biomarker FN-EDB targets a degradation fragment of cellular fibronectin and showed to be elevated in patients with idiopathic pulmonary fibrosis.

    This new biomarker enables quantification of a vital matrix embedded protein – laying the groundwork for important future studies.

    Read article

    Nephrology

    In this study, we explored three collagen type III markers in the kidney’s interstitial matrix. These markers exhibited varied expressions and associations with inflammation, kidney function, and fibrosis in IgA nephropathy patients.

    These findings emphasize the significance of selecting appropriate epitopes for distinct organs and diseases. Notably, urinary C3M emerges as a potential non-invasive fibrosis biomarker, complementing kidney biopsies in IgA nephropathy.

    Read article

    Nephrology

    In our second renal publication, We examined whether collagen type III fragment C3M relates to inflammation markers and endothelial dysfunction, predicting chronic kidney disease (CKD) progression in type 2 diabetes patients with microalbuminuria.

    Inflammatory markers and select endothelial indicators correlated with baseline serum C3M. Doubling serum C3M predicted CKD progression (accounting for mortality risk) post-conventional factor adjustment. These findings highlight serum C3M’s dual role as a CKD risk predictor and inflammation marker in type 2 diabetes.

    Read article

    Get in touch

    Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
    +45 4452 5252 Contact us via email!

      Serological biomarkers are different

      Posted on by Claire Hornung

      Biomarkers are more than just omics categories

      Biomarkers aren’t just confined to different omics categories; various classes are referring to the types of serological measurements.

      Consider cytokines, growth factors, receptors, kinases, transcription factors, intracellular proteins, extracellular proteins, and a subset within that—Extracellular Matrix (ECM) proteins. The common denominator in most pathologies is a loss of balance between different ECM proteins, especially collagens.

      Biomarkers are more than just omics categories

      This excessive destruction and deposition of proteins significantly propel the progression of end-stage diseases, culminating in organ dysfunction, failure, and, ultimately, death.

      Diverse cytokines and growth factors orchestrating via specific receptors and kinases lead to ECM destruction and deposition, making ECM the converging pathway for multiple stimuli.

      By the end of the day, what matters is to reverse ECM deterioration, or even undo, organ damage and function decline. Reversing organ damage can be achieved by stopping ECM deterioration. To truly reverse organ damage and restore organ functionality in patients, we need to repair the ECM to its normal balance.

      We at Nordic Bioscience believe that the answer lies in effecting change at the tissue level—the key to reversing organ damage and, in turn, revitalizing organ function.

      Have you considered if your treatment or pathway is affecting tissue formation or degradation? If so, feel free to browse our unique ECM biomarker portfolio.

      Get in touch

      Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
      +45 4452 5252 Contact us via email!

        Nordic Bioscience’s biomarkers: advantage in dermatology trials

        Posted on by Claire Hornung

        Empower precision medicine in dermatology

        Nordic Bioscience’s extracellular matrix-based dermatology biomarkers offer a unique approach that sets them apart from competitors, providing deeper insights into tissue formation, degradation, immune cell activity, and resolution processes related to skin diseases. Unlike wide-range proteomics arrays, our biomarkers are fundamentally different and more specific, offering a higher level of clarity and precision.

        Nordic Bioscience’s ECM-based dermatology biomarkers offer a unique approach

        A clear connection

        The clear connection between our dermatology biomarkers and skin diseases lies in the fact that immune cell activity, skin tissue remodeling and genetic mutations of collagens are known to cause these conditions. By identifying pathology specific biomarkers, we not only indicate the presence of a disease in a patient but also highlight the local manifestation of an underlying systemic cause. This genetic link and visible manifestation on the skin create a relatable narrative for stakeholders and pharmaceutical companies, potentially paving the way towards a better understanding of the disease.

        A key advantage of our skin disease biomarkers is the limited competition in the market, and no approved biomarkers for skin diseases. With no competitors in the tissue-based biomarker space, we have the opportunity to position ourselves as leaders in this area. Supported by compelling data that demonstrates pathology specificity, disease activity, disease progression, and pharmacodynamic response, there is a rare chance for pharmaceutical partners to be among the first movers and pioneers in this field.

        Moreso, we have observed that skin aging and cross-linking collagens are correlated. Our biomarkers can quantify the age of collagens by measuring alpha and beta CTX-III together with the ECM of the epidermis and dermis.

        Nordic Bioscience can quantify specific pathological fragments from the different compartments of the skin

        Implications for precision medicine

        Precision medicine is a crucial aspect empowered by our dermatology biomarkers. By providing information about ongoing pathological processes within the tissue, such as damage and repair, we enable targeted treatments and therapies that enhance patient outcomes. This personalized medicine approach is far more effective than relying on proteomic providers’ hope of hitting the right target by chance. Our markers aid in drug development by specifically identifying target populations and reducing costs, ultimately expediting the development process.

        Our skin disease biomarkers play a vital role in elucidating the mechanism of action (MoA) of treatments. Here, we can also shed light on the speed at which a compound modulates tissue and fibroblast derived biomarkers, providing essential information on the efficacy and responsiveness of the treatment.

        Furthermore, by analyzing the objective disease activity, we can determine how the compound affects specific factors associated with the patient’s profile, such as neutrophil activity, mast cell activity, macrophage activity, soft tissue destruction, systemic fibroblast activity, and more. This holistic evaluation enables a deeper understanding of how the compound influences different aspects of the disease process, ultimately facilitating the development of more effective and targeted therapies for patients.

        Robust technology

        Our laboratory technology is robust and meets CLSI validation guidelines, ensuring reliability and accuracy. Moreover, our derma markers can be seamlessly integrated into Roche automated platforms, making them easily accessible worldwide. This scalability and dependability are vital for the development of reliable clinical research tools, further solidifying the value of our biomarkers in the field of dermatology.

        A potential case for melanoma studies

        While our dermatology markers have broad applicability, there is a particularly intriguing potential use in melanoma. By understanding the tissue formation, degradation, and repair processes specific to this type of skin cancer, we can offer valuable insights for diagnosis and management.

        For clients involved in ongoing metastatic melanoma research, we can help establish a connection between extracellular matrix remodeling and melanoma, positioning our biomarkers as a valuable resource for further investigation and improving patient care.

        Nordic Bioscience’s ECM-based biomarkers provide a relatable and comprehensive narrative by connecting genetic links, visible skin manifestations, and in-depth insights into ongoing pathological processes. With unparalleled clarity and understanding, our biomarkers empower precision medicine in skin diseases. Supported by robust technology, validated methodologies, and a potential application in melanoma, our biomarkers offer an unprecedented opportunity for stakeholders and pharmaceutical companies.

        Get in touch

        Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
        +45 4452 5252 Contact us via email!

          Serum Calprotectin and Mucosal Damage in IBD

          Posted on by Claire Hornung

          This webinar focuses on the intriguing interplay between inflammatory bowel diseases (IBD) and neutrophil activity, with a special emphasis on the insights provided by the unique CPa9-HNE serum calprotectin.

          Our experts will unravel the biological processes of mucosal damage and healing in inflammatory bowel disease (IBD), and how it relates to neutrophil activity and the extracellular matrix (ECM). Specifically, we will delve into the role of mucosal damage, intestinal fibrosis, and fibro-inflammation, and how they impact ECM remodeling and integrity.

          Watch the replay

          Agenda

          • The role of neutrophil activity in tissue destruction – Dr. Morten A. Karsdal
          • Mucosal damage and intestinal fibrosis in IBD – Dr. Florian Rieder
          • Fibro-inflammation in IBD a new frontier and how to quantify it – Dr. Joachim Høg Mortensen
          • Questions from the chat

          Scientific topics and speakers

          In this edition of the ECM Pharmacology Symposium Series, we will address the mechanisms of neutrophil activity in chronic diseases, in particular on fibro-inflammation in inflammatory bowel diseases, focusing in particular on fibro-inflammation and mucosal damage.

          We will also present the latest methods for quantifying fibro-inflammation in IBD, such as the novel serum calprotectin biomarker CPa9-HNE, and discuss the implications of these findings for patients. In addition, we will look at current and future treatment options for IBD and the potential impact of these advances on patient outcomes.

          This webinar is an excellent opportunity for researchers, clinicians, and healthcare professionals to gain valuable insight into the latest developments in IBD research and treatment, and to gain a deeper understanding of the intricate interplay of neutrophil activity, mucosal damage and fibro-inflammation in IBD.

          Watch the replay

          Florian Rieder, MD

          • Dr. Rieder’s clinical focus is patients with IBD with a special emphasis on the field of pathogenesis, prediction, and therapy of intestinal fibrosis.
          • Dr. Rieder has published over 150 articles (h-index 52) and book chapters and he has been awarded the Sherman Emerging Leaders award.
          • He is the lead author of the ECCO guidelines on Ulcerative colitis and the first ECCO clinical consensus on ‘Diagnosis and Management of Intestinal Fibrosis’. He is a past associate editor of Clinical and Translational Gastroenterology.
          • Dr. Rieder serves as an abstract reviewer for all major GI conferences and on several editorial boards of medical journals.
          • Dr. Rieder has significant ties to the ECCO, having served as the chair of Y-ECCO, a member of the ECCO operational board, a prior Y-ECCO committee member, and a member of the scientific committee.
          • He was the past chair of REACH-IBD and is currently the Co-Chair of the Professional Education Committee of the Crohn’s and Colitis Foundation.
          • Dr. Rieder is the leading Principal Investigator (PI) of the international Stenosis Therapy and Research (STAR) Consortium, which aims to test anti-fibrotic medications in stricturing Crohn’s disease.

          Dr. Joachim Høg Mortensen

          • Dr. Mortensen joined Nordic Bioscience in 2013 and currently serves as Head of Department of Gastrointestinal Diseases.
          • The group’s research activities span from biomarker discovery to preclinical and clinical trial exploration focusing on the development and validation of blood-based biomarkers to quantify fibro-inflammation which covers neutrophil activity, mucosal damage and intestinal fibrosis in serum of patients with gastrointestinal diseases e.g. inflammatory bowel disease.
          • The group’s primary focus is to evaluate pharmacodynamics changes, efficacy and monitoring of response to various treatments using biomarkers reflecting fibro-inflammation.
          • Biomarkers are developed to support and understand fibro-inflammation-associated IBD disease progression and response to treatment, where the biomarkers are applied from target selection to clinical trial monitoring.

          Dr. Morten A. Karsdal

          • Dr. Karsdal chairs the Extracellular Matrix Pharmacology Congress, an influential forum dedicated to advancing drug development by identifying changes in the ECM as common denominators in chronic diseases.
          • Dr. Morten Karsdal joined Nordic Bioscience in 2001 and has been serving as CEO since June 2010.
          • He is a prolific author, with more than 650 peer-reviewed articles to his name, accumulating over 34,000 citations and an h-index of 95.
          • He is renowned for his expertise and commitment to biomarker development, extracellular matrix biology, and disease research, particularly in fibrosis, rheumatology, and diabetes. He possesses extensive experience in clinical trial design and the clinical application of biochemical markers, consulting for major pharmaceutical companies.
          • As an honorary professor of inflammation research at the University of Southern Denmark, Dr. Karsdal supervises PhD students and contributes to advancing scientific knowledge in the field.
          • In 2016, he authored the first edition of “Biochemistry of Collagens, Laminins and Elastin,” published by Elsevier Science, which is now in its 3rd edition, providing a comprehensive overview of structural proteins and their relevance in chronic diseases.
          • Dr. Karsdal’s leadership and contributions to the Nordic Life Science community were recognized with the Arthur D. Little Nordic Life Science Award in 2023, highlighting his outstanding management and leadership achievements.

          Get in touch

          Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
          +45 4452 5252 Contact us via email!

            Transforming Clinical Research

            Posted on by Claire Hornung

            Nordic Bioscience Clinical Laboratory

            In the field of clinical trials, accuracy and reliability are critical to success. For this reason, Nordic Bioscience Laboratory is dedicated to providing the highest quality laboratory services, with a strong focus on data integrity, customer satisfaction, and scientific excellence.

            Our clinical laboratory offers central lab and specialty lab services, including a wide range of diagnostic and exploratory tests that are essential for meeting patients’ care needs and advancing drug development efforts. We use state-of-the-art equipment and technology, as well as a team of highly skilled laboratory professionals, to deliver fast, accurate and reliable results without sacrificing quality.

            Nordic Bioscience Clinical Laboratory offers central and specialty lab services

            Compliance at every step of the way

            We pride ourselves on ensuring that biomarker validation complies with European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines. In addition, we provide access to a team of scientific experts who have the experience and expertise to help you navigate the complexities of biomarker research, interpret data, and make informed decisions about your studies.

            Our Clinical Laboratory is accredited by the College of American Pathologists (CAP) and all aspects of laboratory services are performed in accordance with international Good Clinical Practice (GCP) and Good Clinical laboratory Practices (GCLP) standards. Our accreditation reflects our unwavering commitment to providing the highest quality laboratory services that adhere to the most rigorous industry standards.

            Commitment to improvement

            As part of our ongoing commitment to continuous improvement, our processes, and procedures are regularly reviewed and audited by numerous external auditors and accreditation bodies. These audits enable us to continuously improve and innovate our laboratory services to meet the latest regulatory requirements. We also invest in the continuous education and training of our staff to stay abreast of the latest laboratory science. These efforts allow us to maintain our high-quality standards and ensure that our customers receive the best possible laboratory services, as well as scientific excellence that can help them interpret data.

            At Nordic Bioscience Laboratory, we hold ourselves to the highest standard of quality and place a high value on providing a personalized experience for clinical testing. We are committed to serving as your trusted partner in delivering accurate and reliable laboratory services that help advance the field of clinical trials.

            We hope that you will consider partnering with Nordic Bioscience for your clinical laboratory needs. We look forward to the opportunity to work with you and support your research activities.

            Get in touch

            Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
            +45 4452 5252 Contact us via email!

              Minor Collagen Hypothesis in Cancer

              Posted on by Claire Hornung

              The Minor Collagen Hypothesis

              Collagen is a crucial protein that provides structural support and strength to tissues throughout the body. However, there is a group of highly specialized minor collagens that may play a critical role in cancer progression. Most research on the biology of collagens has focused on the abundant collagens, but the highly specialized minor collagens that are expressed only at certain developmental stages may be deregulated in cancer.

              The Hypothesis

              Minor collagens are widely expressed during embryogenesis, as they organize the extracellular matrix (ECM) to support tissue development. However, in adult tissues, minor collagens become restricted to a few specific organs and are expressed at very low levels.

              Recent studies have suggested that minor collagens may become deregulated in cancer, where they are highly upregulated in tumor tissues. This upregulation is thought to occur as the ECM is reorganized during tumor development and progression. We have chosen to call this hypothesis “The Minor Collagen Hypothesis”. We hypothesize that minor collages, which are normally restricted to embryonic tissues, may become active again in adult tissues as cancer progresses. The Minor Collagen Hypothesis proposes that this reactivation may be a key component in in tumor growth and invasion by altering the composition of the ECM.

              Visualization of the minor collagen hypothesis. Figure by Jeppe Thorlacius-Ussing.

              Applying The Minor Collagen Hypothesis in clinical research

              Biomarkers are important for indicating the presence or severity of a disease, and in cancer, they are crucial for early detection, monitoring of cancer progression, and guiding treatment decisions.

              In general, several collagen biomarkers are overexpressed in cancer. However, minor collagens may offer a more specific biomarker for certain types of cancer. For example, recent research has shown that certain subtypes of cancer-associated fibroblasts (CAFs) express specific minor collagens. These collagens can be detected in blood, making them potential targets for drug development aimed at CAFs.

              This hypothesis offers researchers new possibilities and highlights the need for more specific biomarkers for cancer diagnosis and treatment that could lead to better patient outcomes. Identifying biomarkers that detect specific minor collagens could be a breakthrough in cancer research and might shed light on an overlooked aspect of cancer progression.

              Minor collagens are typically expressed during embryogenesis or tissue development and are expressed at low levels afterward. In cancer, however, these specialized collagens are expressed again to form an environment conducive to cancer growth. The abundant major collagens are also expressed during tissue development and growth spurts in childhood and adolescence but tapers off in adulthood. The relative induction as a function of cancer is greater for the minor collagens compared to the major collagens. This could mean better biomarker performance. 

              Learn more about our cancer biomarkers!

              Get in touch

              Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
              +45 4452 5252 Contact us via email!

                Tumor Fibrosis in Cancer: Fibroblast Activities and New Biomarkers

                Posted on by Claire Hornung

                Watch this insightful webinar on tumor fibrosis, where we will explore the latest advancements in cancer research with leading experts in the field.

                This webinar will provide a unique opportunity to hear from experts in the field and gain valuable insights into the latest advancements in tumor fibrosis research. Join us to learn about cutting-edge approaches to developing new therapeutic targets, and the use of biomarkers for patient stratification and evaluating treatment efficacy.

                Watch the replay here

                Agenda

                Opening of the session – Dr. Morten A. Karsdal

                Tumor Fibrosis and Clinical Outcomes: Underlying Mechanisms – Dr. Saurabh Gupta

                The Collagen Landscape in Cancer: Fibroblast Activities and New Biomarkers – Dr. Nicholas Willumsen 

                Unique and unexpected role of collagens in cancer – Dr. Raghu Kalluri 

                Question from the chat

                Expert line-up

                Dr. Raghu Kalluri (Professor and Chairman, Department of Cancer Biology, University of Texas MD Anderson Cancer Center), is an expert in the cellular microenvironment and will discuss, among others, the unique and unexpected role of collagens in cancer.

                Dr. Saurabh Gupta (Senior Director, Clinical Biomarkers Oncology, Precision Medicine), Bristol-Myers Squibb, is a clinical drug development and biomarker research expert and will provide valuable insights into the underlying mechanisms of tumor fibrosis and the association with clinical outcomes.

                Dr. Nicholas Willumsen (Director, Oncology, Nordic Bioscience), will focus on the development and validation of blood-based biomarkers to quantify tumor fibrosis in serum from cancer patients and discuss how this may inform on cancer-associated fibroblast (CAF) activity and subtyping.

                Get in touch

                Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
                +45 4452 5252 Contact us via email!

                  Bile duct ligation in animal models

                  Posted on by Claire Hornung

                  Understanding Fibrosis Remodeling in Animal Models

                  Animal testing is a crucial aspect of drug development, mandated by the FDA for all premature drugs in development. However, a critical question arises: how can we be sure that the pathology observed in rodents is reflective of the same pathology in humans? This is a significant concern for the medical community because of the potential for negative consequences if clinical trials are based on inaccurate preclinical data as we see in humans. Why then is it so important to measure biomarker formations in rodents? Because it matters whether it mimics the right pathology.

                  Example for bridging preclinical and clinical practice. Bile duct ligation: a preclinical model of liver fibrosis.

                  The process of transitioning from preclinical to clinical trials is critical to success. Histological stages are built on human tissue sections and used for comparison to create an appropriate animal model. However, none of the existing rodent models currently develop nonalcoholic steatohepatitis (NASH) as seen in humans. This discrepancy raises concerns regarding the usefulness of rodent models for preclinical studies.

                  Despite these concerns, it is still essential to measure biomarker formations in rodents. The reason being, it matters whether the biomarker mimics the correct pathology. Nordic Bioscience has demonstrated increasing formation of both type III collagen (interstitial matrix) and type IV collagen (basement membrane) with continued injury in a rat bile duct ligation model. Collagen III has been shown to be upregulated in human liver fibrosis, including NASH, and is associated with increased severity. On the other hand, collagen IV is a measure of early fibrosis remodeling.

                  Bile duct ligation: a preclinical model of liver fibrosis

                  It is critical to understand fibrosis remodeling during disease progression in both animals and humans. With Nordic Bioscience’s biomarkers, researchers can improve translation between the preclinical and clinical practice. The use of biomarkers enables researchers to track disease progression and evaluate the effectiveness of potential treatments accurately. Moreover, they can also help identify patients who are likely to respond positively to a particular therapy.

                  Animal testing remains a critical aspect of drug development, it is essential to understand rodent model limitations. Biomarkers offer an effective way to track the progression of disease accurately. We can identify patients likely to benefit from a specific treatment and improve the transition from preclinical to clinical trials. By leveraging biomarkers in both animal and human models, we can make sure that the right therapy is provided to the right patient—at the right time.

                  Learn more about our fibrosis biomarkers!

                  Get in touch

                  Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
                  +45 4452 5252 Contact us via email!

                    HFpEF and Extracellular Matrix Dysregulation: Novel Treatment Strategies

                    Posted on by Claire Hornung

                    The session will include a stimulating talk by Dr. Morten Karsdal on understanding the mysteries of the different types of collagens. Dr. Alexander Lynge Reese-Petersen will then spotlight collagen type VI and its relationship to various pathologies, as well as the pharmacological and biological properties of the dangerous hormone Endotrophin.

                    Scientific topics

                    Extracellular matrix (ECM) dysregulation is the founding cause of tissue fibrosis, a process driving more than 50 pathologies and most chronic diseases. Fibrosis may develop both consequent to either an increase in tissue formation or a decrease in tissue degradation.

                    ​​​​​​​Understanding the ECM and the central components of the basement membrane and interstitial ECM will lead to a better understanding of disease mechanisms and to novel treatment strategies. This may be a central part in precision medicine strategies to target the right patients.

                    Watch replay here

                    Dr. Morten Karsdal will talk about:

                    • ECM remodeling is the common denominator of all fibro-inflammatory disorders
                    • Collagens have signaling molecules that we need to understand to understand how the ECM affects cells in fibrosis and tissue turnover
                    • Endotrophin and other collagen fragments (Vastatin, Tumstatin and Endostatin) are potential signaling molecules derived from the processing of the collagens in the ECM
                    • Understanding ECM turnover may lead to better insight into disease mechanisms and better biological understanding of individual patients

                    Dr. Alexander Reese’s presentation will cover:

                    • ECM biomarkers are elevated in chronic pathologies and have prognostic significance for outcome. How can we best use this to guide drug development?
                    • Endotrophin, a collagen hormone in multi-organ diseases
                    • Endotrophin in HFpEF, a potentially treatable high-risk endotype
                    • Use of the tissue turnover profile for patient selection

                    Get in touch

                    Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
                    +45 4452 5252 Contact us via email!